Sentences with phrase «development of therapy»

Some key individuals in the development of this therapy and their contributions to the field include:

This has resulted in the development of therapy dog programs that specialize in comforting victims and first responders following disasters.

Retrophin is a publicly - held biopharmaceutical company focused on the development of therapies for the treatment of serious, catastrophic, or rare diseases.

Further studies into this relationship could lead to the development of therapies that treat disorders such as obesity and diabetes.

In addition, the development of therapies that could potentially halt patients» progression from pancreatic inflammation to diabetes has been hampered by the long lead times needed in order to tell whether a given therapy has an effect.

These deletions also may extend to neighboring genes, an event known as «collateral lethality,» which may create new options for development of therapies for several cancers.

«This could have profound implications for the development of therapies that include such approaches as interferon alpha therapy,» Zhen said.

By staying abreast of the development of these therapies, the NFL will protect itself and its players by enabling new and beneficial treatments while curbing illegitimate and unsafe usage.»

Therefore, the insights of Dr. Melendez and her colleagues may deepen our understanding of cancer and aid in the development of therapies against malignant cell growth.

«Medicine is advancing toward the development of therapies tailored to the needs of each patient,» Marson said.

«The microbiome appears to shape a patient's response to cancer immunotherapy, which opens potential pathways to use it to assess a patient's fitness for immunotherapy and to manipulate it to improve treatment,» said Wargo, who is also co-leader of the Melanoma Moon Shot ™, part of MD Anderson's Moon Shots Program ™ to reduce cancer deaths by accelerating development of therapies from scientific discoveries.

«It opens a possible new avenue for the development of therapies that may be promising for slowing or stopping the effects of Alzheimer's disease, traumatic brain injury and spinal cord injury.»

It is expected the breakthrough could have a major impact on the development of therapies for a variety of diseases, including cancer.

This information could provide new possibilities for the development of therapies for cancer.

We're excited about the implications of our research for treating muscle diseases, and look forward to applying our conclusions toward development of therapies.»

New leads on alpha - synuclein could also aid the development of therapies targeting the protein.

«Our findings point to two potential impacts from additional research — analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment,» said Wargo, senior researcher on the project and co-leader of the Melanoma Moon Shot ™, part of MD Anderson's Moon Shots Program ™ to reduce cancer deaths by accelerating development of therapies from scientific discoveries.

Dr. Petrucelli and his team think these results are an important step in the development of therapies for these forms of ALS and FTD and other neurodegenerative disorders.

The platform is part of MD Anderson's Moon Shots Program, launched in 2013 to reduce cancer deaths by accelerating development of therapies, prevention efforts and early detection from scientific discoveries.

Although we agree that greater investments are needed in the clinical development of these therapies, we disagree with the authors» suggestion that, relative to embryonic stem cells, adult stem cells provide a superior vehicle for cell - based therapies because they lack tumorigenic activity, can be prepared by methods approved by the Food and Drug Administration (FDA), and have been free of ethical controversy.

Taken together with Open Science model and patent - free access to all outputs, it is expected that the ALS - RAP will galvanize and enable a faster and even more efficient development of therapies to address the ALS challenge, globally.

«We are entering an exciting period of discoveries in genetics that may provide new insights about novel disease pathways that can be explored for development of therapies.»

«Identifying druggable targets that participate during the pre-symptomatic stage of the disease is particularly important,» Nishina says, «to enable development of therapies that can prevent, delay onset or decrease the severity of RPE - associated diseases irrespective of the initial cause of the disease.»

So while biotechnology has advanced by leaps and bounds on every side, every individual along the way made a rational short - term decision not to touch this area of research - and this despite the fact that it is a big, obvious target for the development of therapies that could help to extend healthy life and treat or prevent a wide range of age - related conditions that cause a great deal of suffering and death.

For example, the discovery of cancer - causing genetic and epigenetic changes in tumors has enabled the development of therapies that target these changes as well as diagnostic tests that identify patients who may benefit from these therapies.

His work will inform future development of therapies and diagnostics for conditions including amyotrophic lateral sclerosis (ALS) and spinal motor atrophy.

The autoimmune therapeutic area represents a broad category of human disease presentations that involve a variety of organ targets and thus presents a significant challenge with respect to the development of therapies designed to re-establish self - tolerance.

«The strong evidence that abnormal TDP - 43 protein is involved in the development of ALS, coupled with models that may replicate ALS more faithfully than other tools, may speed development of therapies for the thousands of individuals diagnosed with this devastating disease.»

Understanding Zika's mechanisms will illuminate how viral infection leads to birth defects such as microcephaly, a condition marked by an abnormally small head and brain size, and could inform the development of therapies and vaccines, the study authors said.

In order to accelerate the development of therapies to bring aging under full medical control, the Forever Healthy Foundation directly supports cutting - edge research aimed at the molecular and cellular repair of damage caused by the aging process.

If the team's study shows that TLR2 activation is involved in the development and progression of AMD, they will have identified a new pathway for the targeted development of therapies for AMD.

The goal of the study was to identify additional oncogenic alterations to provide a framework for further research and guide development of therapies.

The development of therapies like SRK - 015 that directly tackle muscle atrophy by itself or in combination with SMN - upregulating therapies is now the next frontier.»

Not exact matches

The first move sets Takeda up to work on development of FIN - 524, a preclinical therapy that contains cultured bacteria strains and which could theoretically be used to treat gut diseases.

Right now, the first CRISPR gene therapies are in development, but they are not built on a «standard stack» and require a lot of custom work for each indication - these therapies will be coming into the clinic and hopefully get approved the coming couple years, and after that there could be significantly more investment into standard tools.»

Outlook: According to Employment and Social Development Canada, audiologists and speech - language pathologists (part of the «therapy and assessment professionals» occupation class) should find a fairly balanced job market into 2020, with the number of job seekers nearly matching the number of available positions over the next few years.

Today, I offer a third prediction — this one in the realm of drug development: RNA - based therapies will shine as never before.

«As a part of the Nohla team, I look forward to advancing the development of its cell therapy programs for patients with significant unmet needs.»

And there have been developments in cellular therapies to treat cancer, with two treatments aiming for approval by the end of 2017.

Announced a worldwide collaboration with Sangamo Therapeutics, Inc. (Sangamo) using Sangamo's zinc finger nuclease technology platform for the development of next - generation ex vivo cell therapies in oncology.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Further, we believe R&D NewCo will be strongly positioned to continue Actelion's legacy of innovation and look forward to collaborating on the development of cutting - edge new therapies.»

The company is also seeking deeper inroads into rare diseases, with a number of assets in late - stage development, and last year it scored a major regulatory win when Europe approved its «bubble boy syndrome» gene therapy Strimvelis.

Minoryx is a clinical stage biotech company leading the development of new therapies for X-linked Adrenoleukodystrophy (X-ALD) and other inborn errors of metabolism, a group of rare diseases of genetic origin with a high unmet medical need.

Such an approach does not prevent the development of the AMN form, for which there are no therapies available.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases.

Prior to being elected, Selina had a home - based family therapy practice, was the Director of Development for SHARE Family and Community Services and was a Counselling Instructor and Program Developer at the University of British Columbia's Life and Learning Centre and Vancouver Community College.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develTherapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The injection will bankroll the continuing technical development of the firm's first LIGHT system and its installation at the Harley Street Proton Therapy Centre